• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗性粪菌移植:现状与未来发展。

Therapeutic faecal microbiota transplantation: current status and future developments.

机构信息

aCentre of Digestive Diseases, Sydney, New South Wales, Australia bAlbert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA cSt Vincent's Hospital Clinical School, Darlinghurst, New South Wales, Australia.

出版信息

Curr Opin Gastroenterol. 2014 Jan;30(1):97-105. doi: 10.1097/MOG.0000000000000027.

DOI:10.1097/MOG.0000000000000027
PMID:24257037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3868025/
Abstract

PURPOSE OF REVIEW

Faecal microbiota transplantation (FMT) has undergone dramatic progression over the past year and continues to evolve as knowledge of the gastrointestinal microbiota (GiMb) develops. This review summarizes therapeutic advances in FMT, latest FMT therapies and presents the potential of FMT therapeutics in other gastrointestinal and extra-intestinal conditions.

RECENT FINDINGS

The GiMb is now known to have a central role in the pathogenesis of many diseases. The success of FMT in curing Clostridium difficile infection (CDI) is well established and preliminary findings in other gastrointestinal conditions are promising. Published data from over 500 CDI cases suggest that FMT is generally well tolerated with minimal side effects. The commercial potential of FMT is being explored with several products under development, including frozen GiMb extract, which has been shown highly effective in treating relapsing CDI. Such products will likely become more available in coming years and revolutionize the availability and method of delivery of GiMb.

SUMMARY

Recent literature unequivocally supports the use of FMT in treating relapsing CDI. Trials are underway to determine the therapeutic potential of FMT in other conditions, particularly inflammatory bowel disease. Therapeutic FMT is a dynamic field with new and emerging indications along with ongoing developments in optimal mode of administration.

摘要

目的综述

粪菌移植(FMT)在过去一年中取得了显著进展,随着对胃肠道微生物组(GiMb)的认识不断发展,它仍在不断演变。本综述总结了 FMT 的治疗进展、最新的 FMT 疗法,并介绍了 FMT 疗法在其他胃肠道和肠道外疾病中的潜力。

最近的发现

现在已知 GiMb 在许多疾病的发病机制中起着核心作用。FMT 治疗艰难梭菌感染(CDI)的成功已得到充分证实,其他胃肠道疾病的初步发现也很有希望。超过 500 例 CDI 病例的发表数据表明,FMT 通常具有良好的耐受性,副作用极小。FMT 的商业潜力正在被探索,包括冷冻 GiMb 提取物在内的几种产品正在开发中,已证明其在治疗复发性 CDI 方面非常有效。此类产品可能在未来几年内更广泛地应用,并彻底改变 GiMb 的获取和给药方式。

总结

最近的文献明确支持 FMT 用于治疗复发性 CDI。正在进行试验以确定 FMT 在其他疾病(特别是炎症性肠病)中的治疗潜力。治疗性 FMT 是一个充满活力的领域,随着最佳给药方式的不断发展,新的和新兴的适应症也在不断涌现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9a/3868025/ca1959662bc9/cogas-30-97-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9a/3868025/e40bc03f55fd/cogas-30-97-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9a/3868025/7b536bd5f555/cogas-30-97-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9a/3868025/ca1959662bc9/cogas-30-97-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9a/3868025/e40bc03f55fd/cogas-30-97-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9a/3868025/7b536bd5f555/cogas-30-97-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9a/3868025/ca1959662bc9/cogas-30-97-g003.jpg

相似文献

1
Therapeutic faecal microbiota transplantation: current status and future developments.治疗性粪菌移植:现状与未来发展。
Curr Opin Gastroenterol. 2014 Jan;30(1):97-105. doi: 10.1097/MOG.0000000000000027.
2
Fecal microbiota transplantation: indications, methods, evidence, and future directions.粪便微生物群移植:适应症、方法、证据及未来方向。
Curr Gastroenterol Rep. 2013 Aug;15(8):337. doi: 10.1007/s11894-013-0337-1.
3
Fecal microbiota transplantation: past, present and future.粪便微生物移植:过去、现在和未来。
Curr Opin Gastroenterol. 2013 Jan;29(1):79-84. doi: 10.1097/MOG.0b013e32835a4b3e.
4
Fecal microbiota transplantation: facts and controversies.粪便微生物移植:事实与争议。
Curr Opin Gastroenterol. 2014 Jan;30(1):34-9. doi: 10.1097/MOG.0000000000000024.
5
An overview of fecal microbiota transplantation: techniques, indications, and outcomes.粪便微生物群移植概述:技术、适应症及结果
Gastrointest Endosc. 2013 Aug;78(2):240-9. doi: 10.1016/j.gie.2013.03.1329. Epub 2013 May 2.
6
Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs.粪便微生物移植治疗复发性艰难梭菌感染:现状与未来需求。
Curr Opin Gastroenterol. 2013 Nov;29(6):628-32. doi: 10.1097/MOG.0b013e328365d326.
7
Fecal microbiota transplantation for Clostridium difficile infection: benefits and barriers.粪便微生物群移植治疗艰难梭菌感染:获益与障碍。
Curr Opin Gastroenterol. 2014 Jan;30(1):47-53. doi: 10.1097/MOG.0000000000000023.
8
Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?粪便微生物移植在肠道疾病以外有潜在的应用吗?
Biomed Res Int. 2019 Jul 29;2019:3469754. doi: 10.1155/2019/3469754. eCollection 2019.
9
Fecal microbiota transplantation in treating Clostridium difficile infection.粪便微生物群移植治疗艰难梭菌感染
J Dig Dis. 2014 Aug;15(8):405-8. doi: 10.1111/1751-2980.12160.
10
Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.微生物群移植可恢复复发性艰难梭菌感染患者的正常粪便胆汁酸组成。
Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310-9. doi: 10.1152/ajpgi.00282.2013. Epub 2013 Nov 27.

引用本文的文献

1
The functional landscape of the appendix microbiome under conditions of health and disease.健康与疾病状态下阑尾微生物群的功能图谱。
Gut Pathog. 2025 Jun 1;17(1):38. doi: 10.1186/s13099-025-00696-2.
2
Fecal Microbiota Transplantation: Insights into Colon Carcinogenesis and Immune Regulation.粪便微生物群移植:对结肠癌发生和免疫调节的见解。
J Clin Med. 2024 Nov 1;13(21):6578. doi: 10.3390/jcm13216578.
3
Gut-Brain Interactions and Their Impact on Astrocytes in the Context of Multiple Sclerosis and Beyond.肠脑相互作用及其对多发性硬化症及其他疾病中天麻素星形胶质细胞的影响。

本文引用的文献

1
Treatment of Recurrent Diarrhea.复发性腹泻的治疗
Gastroenterol Hepatol (N Y). 2006 Mar;2(3):203-208.
2
Fecal microbiota transplantation: indications, methods, evidence, and future directions.粪便微生物群移植:适应症、方法、证据及未来方向。
Curr Gastroenterol Rep. 2013 Aug;15(8):337. doi: 10.1007/s11894-013-0337-1.
3
Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection.粪便微生物群移植:艰难梭菌感染的一种新的标准治疗选择。
Cells. 2024 Mar 13;13(6):497. doi: 10.3390/cells13060497.
4
Gut-Brain Axis Modulation of Metabolic Disorders: Exploring the Intertwined Neurohumoral Pathways and Therapeutic Prospects.肠道-大脑轴对代谢紊乱的调节:探索相互交织的神经激素途径和治疗前景。
Neurochem Res. 2024 Apr;49(4):847-871. doi: 10.1007/s11064-023-04084-7. Epub 2024 Jan 20.
5
The Crosstalk between Gut Microbiota and Nervous System: A Bidirectional Interaction between Microorganisms and Metabolome.肠道微生物群与神经系统的串扰:微生物群和代谢组之间的双向相互作用。
Int J Mol Sci. 2023 Jun 19;24(12):10322. doi: 10.3390/ijms241210322.
6
The Intestinal and Skin Microbiome in Patients with Atopic Dermatitis and Their Influence on the Course of the Disease: A Literature Review.特应性皮炎患者的肠道和皮肤微生物群及其对疾病进程的影响:文献综述
Healthcare (Basel). 2023 Mar 6;11(5):766. doi: 10.3390/healthcare11050766.
7
The Role of Gut Microbiota in Various Neurological and Psychiatric Disorders-An Evidence Mapping Based on Quantified Evidence.肠道微生物群在各种神经和精神疾病中的作用——基于量化证据的证据图谱。
Mediators Inflamm. 2023 Feb 8;2023:5127157. doi: 10.1155/2023/5127157. eCollection 2023.
8
The Role of Fecal Microbiota Transplantation in the Treatment of Neurodegenerative Diseases: A Review.粪便微生物移植在神经退行性疾病治疗中的作用:综述。
Int J Mol Sci. 2023 Jan 5;24(2):1001. doi: 10.3390/ijms24021001.
9
Fecal Microbiota Transplantation Reduces Pathology and Improves Cognition in a Mouse Model of Alzheimer's Disease.粪便微生物移植可减轻阿尔茨海默病模型小鼠的病理改变并改善认知功能。
Cells. 2022 Dec 28;12(1):119. doi: 10.3390/cells12010119.
10
Fecal Microbiota Transplantation Role in the Treatment of Alzheimer's Disease: A Systematic Review.粪便微生物群移植在阿尔茨海默病治疗中的作用:一项系统综述
Cureus. 2022 Oct 6;14(10):e29968. doi: 10.7759/cureus.29968. eCollection 2022 Oct.
Expert Rev Anti Infect Ther. 2013 May;11(5):447-9. doi: 10.1586/eri.13.26.
4
Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis.粪便移植治疗儿童和青年溃疡性结肠炎的安全性、耐受性和临床应答。
J Pediatr Gastroenterol Nutr. 2013 Jun;56(6):597-601. doi: 10.1097/MPG.0b013e318292fa0d.
5
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.艰难梭菌感染的诊断、治疗和预防指南。
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499. doi: 10.1038/ajg.2013.4. Epub 2013 Feb 26.
6
Duodenal infusion of donor feces for recurrent Clostridium difficile.经十二指肠输注供体粪便治疗复发性艰难梭菌感染。
N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.
7
American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection.美国胃肠病学杂志讲座:肠道微生物群及粪便微生物群移植(FMT)在治疗艰难梭菌感染中的作用。
Am J Gastroenterol. 2013 Feb;108(2):177-85. doi: 10.1038/ajg.2012.450. Epub 2013 Jan 15.
8
Should we standardize the 1,700-year-old fecal microbiota transplantation?我们应该规范有1700年历史的粪便微生物群移植吗?
Am J Gastroenterol. 2012 Nov;107(11):1755; author reply p.1755-6. doi: 10.1038/ajg.2012.251.
9
Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice.用简单、明确的细菌疗法靶向修复肠道微生物群可解决小鼠复发性艰难梭菌病。
PLoS Pathog. 2012;8(10):e1002995. doi: 10.1371/journal.ppat.1002995. Epub 2012 Oct 25.
10
Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome.分析旧秩序阿米什人的肠道微生物群及其与代谢综合征的关系。
PLoS One. 2012;7(8):e43052. doi: 10.1371/journal.pone.0043052. Epub 2012 Aug 15.